
TRVI Stock Forecast & Price Target
TRVI Analyst Ratings
Bulls say
Trevi Therapeutics Inc. has demonstrated notable progress by successfully completing its End-of-Phase 2 meeting with the U.S. Food and Drug Administration, which reinforces the anticipated timelines for its investigational therapy, Haduvio. The therapy’s unique clinical profile, which includes statistically significant reductions in cough frequency across multiple chronic cough populations, highlights the substantial market opportunity available to the company. Overall, Trevi Therapeutics is viewed as a high-quality investment, with potential for success through both independent operations and strategic partnerships.
Bears say
Trevi Therapeutics Inc faces several significant challenges that contribute to a negative outlook for its stock, primarily related to competitive pressure and reimbursement uncertainty which may hinder its revenue potential. Additionally, the company is exposed to regulatory and trial risks, alongside concerns about capital requirements and operational dependence. These factors combined suggest that despite the potential for Haduvio to generate substantial revenue, the risks involved could severely impact its market performance.
This aggregate rating is based on analysts' research of Trevi Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
TRVI Analyst Forecast & Price Prediction
Start investing in TRVI
Order type
Buy in
Order amount
Est. shares
0 shares